BGNE insider transaction filings
BeiGene, Ltd. — 29 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-05-23. Screen BGNE transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-05-23 | 4 | Yi Qingqing — Director | Grant/award (A): 10,985 @ $0 · Grant/award (A): 22,750 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Riva Alessandro — Director | Grant/award (A): 10,985 @ $0 · Grant/award (A): 22,750 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Dugan Margaret — Director | Grant/award (A): 10,985 @ $0 · Grant/award (A): 22,750 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Sanders Corazon (Corsee) D. — Director | Grant/award (A): 10,985 @ $0 · Grant/award (A): 22,750 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | BRANDICOURT OLIVIER — Director | Grant/award (A): 10,985 @ $0 · Grant/award (A): 22,750 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Sharp Shalini — Director | Grant/award (A): 10,985 @ $0 · Grant/award (A): 22,750 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | HOOPER ANTHONY C — Director | Grant/award (A): 10,985 @ $0 · Grant/award (A): 22,750 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | Wang Xiaodong — Director | Option exercise (M): 41,760 @ $6.50 · Sale (S): 10,221 @ $222.83 · Sale (S): 21,235 @ $223.41 · Sale (S): 10,104 @ $224.32 · Sale (S): 200 @ $225.68 · Option exercise (M): 542,880 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | OYLER JOHN — Chief Executive Officer, Director | Option exercise (M): 4,055,415 @ $0.50 · Tax withholding (F): 1,990,603 @ $17.85 · Option exercise (M): 4,055,415 (derivative) @ $0 | EDGAR |
| 2025-04-16 | 4 | Wang Xiaodong — Director | Option exercise (M): 41,760 @ $6.50 · Sale (S): 995 @ $237.56 · Sale (S): 805 @ $238.48 · Sale (S): 2,884 @ $239.51 · Sale (S): 5,516 @ $240.41 · Sale (S): 2,229 @ $241.51 · +9 more | EDGAR |
| 2025-04-03 | 4 | Wu Xiaobin — President, COO & GM China | Option exercise (M): 16,477 @ $119.96 · Option exercise (M): 35,444 @ $174.43 · Sale (S): 28,253 @ $280.31 · Sale (S): 6,364 @ $281.67 · Sale (S): 12,221 @ $282.76 · Sale (S): 5,083 @ $283.79 · +2 more | EDGAR |
| 2025-03-20 | 4 | Wang Xiaodong — Director | Option exercise (M): 41,760 @ $6.50 · Sale (S): 2,417 @ $258.25 · Sale (S): 6,926 @ $259.08 · Sale (S): 2,694 @ $259.86 · Sale (S): 10,448 @ $261.44 · Sale (S): 11,245 @ $262.12 · +3 more | EDGAR |
| 2025-03-18 | 4 | Wu Xiaobin — President, COO & GM China | Sale (S): 0 @ $0 | EDGAR |
| 2025-03-13 | 4 | Wang Xiaodong — Director | Gift (G): 158,717 @ $0 | EDGAR |
| 2025-03-12 | 4 | OYLER JOHN — Chief Executive Officer, Director | Option exercise (M): 497,822 @ $0.50 · Option exercise (M): 41,210 @ $6.50 · Sale (S): 1,900 @ $238.74 · Sale (S): 6,800 @ $239.59 · Sale (S): 2,200 @ $240.70 · Sale (S): 7,069 @ $241.92 · +6 more | EDGAR |
| 2025-03-07 | 4 | Wu Xiaobin — President, COO & GM China | Grant/award (A): 103,883 @ $0 · Option exercise (M): 7,048 @ $169.65 · Option exercise (M): 44,873 @ $119.96 · Sale (S): 17,824 @ $260.39 · Sale (S): 11,360 @ $261.61 · Sale (S): 22,537 @ $262.51 · +3 more | EDGAR |
| 2025-03-07 | 4 | Wang Lai — Global Head of R&D | Grant/award (A): 69,251 @ $0 | EDGAR |
| 2025-03-07 | 4 | Lee Chan Henry — SVP, General Counsel | Grant/award (A): 40,209 @ $0 | EDGAR |
| 2025-03-07 | 4 | Rosenberg Aaron — Chief Financial Officer | Grant/award (A): 48,581 @ $0 | EDGAR |
| 2025-03-07 | 4 | OYLER JOHN — Chief Executive Officer, Director | Option exercise (M): 708,747 @ $0.50 · Option exercise (M): 58,590 @ $6.50 · Sale (S): 1,400 @ $246.03 · Sale (S): 2,100 @ $246.09 · Sale (S): 1,190 @ $246.69 · Sale (S): 13,918 @ $246.91 · +10 more | EDGAR |
| 2025-03-07 | 4 | OYLER JOHN — Chief Executive Officer, Director | Grant/award (A): 201,084 @ $0 · Option exercise (M): 486,161 @ $0.50 · Option exercise (M): 40,109 @ $6.50 · Sale (S): 3,500 @ $256.91 · Sale (S): 13,598 @ $257.92 · Sale (S): 8,200 @ $258.91 · +6 more | EDGAR |
| 2025-03-06 | 4 | Wang Xiaodong — Director | Sale (S): 700 @ $251.70 · Sale (S): 2,000 @ $252.72 · Sale (S): 825 @ $253.55 · Sale (S): 1,275 @ $254.77 · Sale (S): 1,214 @ $255.71 · Sale (S): 1,809 @ $256.83 · +1 more | EDGAR |
| 2025-03-05 | 4 | OYLER JOHN — Chief Executive Officer, Director | Option exercise (M): 1,220,531 @ $0.50 · Option exercise (M): 101,000 @ $6.50 · Sale (S): 5,956 @ $240.53 · Sale (S): 13,816 @ $241.38 · Sale (S): 8,192 @ $242.46 · Sale (S): 11,195 @ $243.44 · +9 more | EDGAR |
| 2025-03-04 | 4 | Wu Xiaobin — President, COO & GM China | Sale (S): 0 @ $0 | EDGAR |
| 2025-03-03 | 4 | Lee Chan Henry — SVP, General Counsel | Sale (S): 1,205 @ $275 | EDGAR |
| 2025-02-25 | 4 | Wang Lai — Global Head of R&D | Sale (S): 1,327 @ $254.82 · Sale (S): 575 @ $255.86 · Sale (S): 479 @ $256.70 · Sale (S): 437 @ $258.18 · Sale (S): 1,782 @ $258.73 · Sale (S): 400 @ $260.17 | EDGAR |
| 2025-02-25 | 4 | Lee Chan Henry — SVP, General Counsel | Sale (S): 504 @ $256.84 · Sale (S): 598 @ $258.69 · Sale (S): 100 @ $260.21 | EDGAR |
| 2025-02-20 | 4 | Wu Xiaobin — President, COO & GM China | Option exercise (M): 30,654 @ $169.65 · Sale (S): 19,576 @ $240.31 · Sale (S): 7,919 @ $241.26 · Sale (S): 3,159 @ $242.08 · Option exercise (M): 21,267 @ $169.65 · Sale (S): 21,267 @ $240.07 · +2 more | EDGAR |
| 2025-02-06 | 4 | Wang Xiaodong — Director | Option exercise (M): 41,760 @ $6.50 · Sale (S): 9,099 @ $223.00 · Sale (S): 1,519 @ $224.18 · Sale (S): 2,161 @ $225.27 · Sale (S): 17,805 @ $226.35 · Sale (S): 9,776 @ $227.00 · +2 more | EDGAR |
Recent 8-K events — BeiGene, Ltd.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-19 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2025-12-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-11-19 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BGNE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →